As a result of AHA’s successful litigation to stop the Centers for Medicare & Medicaid Services’ unlawful 340B payment policy in calendar year 2022, Medicare Administrative Contractors will pay 340B hospitals Average Sales Price plus 6%, rather than ASP minus 22.5%, for all CY 2022 drug claims with modifier “JG,” the Center for Medicare and Medicaid Services confirmed for AHA yesterday. Judge Rudolph Contreras of the U.S. District Court for the District of Columbia on Sept. 18 ordered CMS to immediately halt its unlawful outpatient payment reimbursement for certain 340B hospitals. 

Affected 340B hospitals should reach out to their MAC if the contractor has not notified them about the adjustment to ensure eligible 2022 claims for drugs provided before Sept. 28 are adjusted. CMS will auto-process any claims after Sept. 28, as previously announced on its website.  

AHA called the clarification a significant victory for 340B hospitals subject to the outpatient prospective payment system cuts in CY 2022, which will help them to continue to serve their communities. 

Related News Articles

Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…